Massive Bio, a startup in precision medicine and artificial intelligence (AI) enabled patient centric clinical trial enrollment, raised $9 million co-led by Revo Capital and Kenan Turnacioglu, Chair of Board of Directors PaigeAI; with additional participation from DEG - Deutsche Investitions- und Entwicklungsgesellschaft mbH, the German Development Finance Institution.

Massive Bio's mission is to provide access to clinical trials for every cancer patient regardless of his/her location and/or financial stability. Massive Bio is an Artificial Intelligence (AI)-driven platform connecting cancer patients and their community oncologists to bio-pharmaceutical clinical trials yielding profound improvement in access and match rates, leading to faster drug development timelines and creating novel oncology data ecosystem for improved protocol design and real-world insights. Massive Bio controls patient enrollment value chain starting patient identification, following with AI based virtual pre-screening outside the site and resolving last mile issues for clinical trial enrollment. While improving cancer patients' lives, Massive Bio serves close to two dozen pharmaceutical companies and contract research organizations (CROs) and providing patient recruitment, site selection and real-world data services in oncology.